泌尿系统恶性肿瘤患者全身炎症反应指数与预后的显著关联。
Significant association between systemic inflammation response index and prognosis in patients with urological malignancies.
作者信息
Ma Wangbin, Liu Rongqiang, Li Xinyi, Yu Jia, Wang Weixing
机构信息
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Laboratory of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
出版信息
Front Immunol. 2025 Feb 26;16:1518647. doi: 10.3389/fimmu.2025.1518647. eCollection 2025.
BACKGROUND
The systemic inflammation response index (SIRI) as an immune marker, is associated with prognosis of urological malignancies(UM). However, the conclusion remains controversial. Therefore, the objective of this study was to conduct a meta-analysis to comprehensively evaluate the predictive value of SIRI in patients with UM.
METHODS
A comprehensive search of PubMed, Web of Science, and EMBASE databases was performed for articles investigating the association between SIRI and UM. The search deadline was August 28, 2024. Survival outcome such as overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS) were analyzed.
RESULTS
15 studies from 13 articles involving 4985 patients were included in the meta-analysis. The results showed that increased SIRI was associated with poorer OS (HR: 2.16, 95% CI: 1.61-2.89) and DFS/PFS/RFS (HR: 3.56, 95% CI: 1.41-8.99). Subgroup analysis further confirmed the prognostic value of SIRI in urinary system cancer.
背景
全身炎症反应指数（SIRI）作为一种免疫标志物，与泌尿生殖系统恶性肿瘤（UM）的预后相关。然而，该结论仍存在争议。因此，本研究的目的是进行一项荟萃分析，以全面评估SIRI在UM患者中的预测价值。
方法
对PubMed、Web of Science和EMBASE数据库进行全面检索，查找研究SIRI与UM之间关联的文章。检索截止日期为2024年8月28日。分析总生存期（OS）、无病生存期（DFS）、无进展生存期（PFS）和无复发生存期（RFS）等生存结局。
结果
荟萃分析纳入了来自13篇文章的15项研究，涉及4985例患者。结果显示，SIRI升高与较差的OS（风险比：2.16，95%置信区间：1.61-2.89）以及DFS/PFS/RFS（风险比：3.56，95%置信区间：1.41-8.99）相关。亚组分析进一步证实了SIRI在泌尿系统癌症中的预后价值。
Zotero 插件